Studies on cefuroxime axetil (CXM-AX)-its skin tissue levels and clinical efficacy

Atsushi Kukita, Hidemi Nakagawa, Shinichi Watanabe, Masataka Oji, Masutaka Furue, Michiro Shimozuma, Ryoji Watanabe, Takashi Eto, Ken Iozumi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The fundamental and clinical studies were performed on Cefuroxime axetil (CXM-AX, SN 407), a new oral cephalosporin, prodrug of Cefuroxime (CXM). The results are summarised below. 1. The mean serum levels of CXM at 120–150 minutes after oral administration of 250 mg and 500 mg of CXM-AX were 3. 25 μg/ml and 4. 30 μg/ml, and the corresponding mean skin tissue levels were 1.46 μg/g and 2.14 μg/g, respectively. The rates of transfer of CXM into skin tissues were 44.9% and 59.5%, respectively, showing dose response between 250 mg and 500 mg groups. 2. Out of 234 cases assessable for clinical efficacy, 122 cases were assessed as Cured, 58 Remarkably Improved, 28 Moderately Improved, 20 Slightly Improved, 5 Unchanged and 1 Aggravated, with the efficacy rate (“Moderately Improved” or better) being 88. 9%. When the clinical efficacy was compared among groups of different diagnosis, the efficacy rates were 81.4% (35/43) in the Group I, 92.5% (37/40) in the Group II, 95.7% (22/23) in the Group III, 90.9% (40/44) in the Group IV, 94.6% (53/56) in the Group V and 75. 0% (21/28) in the Group VI. 3. Concerning the bacteriological response of the causative organisms, isolated from 169 patients, the bacterial elimination rate was 92. 3% (132/143). The MIC peaks of CXM, against 96 strains of S. aureus and 39 strains of coagulase negative staphylococci (CNS), both of which were the major clinical isolates, were 1.56 μg/ml and 0. 78 μg/ml, respectively. The antibacterial activity of CXM was higher than that of Cephalexin (CEX) and comparable to that of Cefaclor (CCL). 4. Among 245 cases in which the safety of the drug was evaluated, adverse events were observed in 17 cases (6. 9%), most of them being gastrointestinal tract symptoms, c. g. diarrhoea, loose stool and gastric pain. The abnormal laboratory findings were noted in a total of 11 cases, i. e. decrease in WBC counts in 2 cases (1.4%), increase in eosinophil counts in 1 (0.7%), elevation of hepatic transaminase levels in 7 (5. 0%) and positive reaction in direct Coombs’ test in 1 (5. 6%).

Original languageEnglish
Pages (from-to)967-1005
Number of pages39
JournalChemotherapy
Volume34
DOIs
Publication statusPublished - Jan 1 1986
Externally publishedYes

Fingerprint

cefuroxime axetil
Cefuroxime
Skin
Cefaclor
Cephalexin
Coombs Test
Coagulase
Prodrugs
Cephalosporins
Transaminases
Staphylococcus
Eosinophils
Oral Administration
Gastrointestinal Tract
Diarrhea
Stomach
Safety
Pain

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

Cite this

Studies on cefuroxime axetil (CXM-AX)-its skin tissue levels and clinical efficacy. / Kukita, Atsushi; Nakagawa, Hidemi; Watanabe, Shinichi; Oji, Masataka; Furue, Masutaka; Shimozuma, Michiro; Watanabe, Ryoji; Eto, Takashi; Iozumi, Ken.

In: Chemotherapy, Vol. 34, 01.01.1986, p. 967-1005.

Research output: Contribution to journalArticle

Kukita, A, Nakagawa, H, Watanabe, S, Oji, M, Furue, M, Shimozuma, M, Watanabe, R, Eto, T & Iozumi, K 1986, 'Studies on cefuroxime axetil (CXM-AX)-its skin tissue levels and clinical efficacy', Chemotherapy, vol. 34, pp. 967-1005. https://doi.org/10.11250/chemotherapy1953.34.Supplement5_967
Kukita, Atsushi ; Nakagawa, Hidemi ; Watanabe, Shinichi ; Oji, Masataka ; Furue, Masutaka ; Shimozuma, Michiro ; Watanabe, Ryoji ; Eto, Takashi ; Iozumi, Ken. / Studies on cefuroxime axetil (CXM-AX)-its skin tissue levels and clinical efficacy. In: Chemotherapy. 1986 ; Vol. 34. pp. 967-1005.
@article{44b9600a9f0c4d7b9483de9b3946b6ce,
title = "Studies on cefuroxime axetil (CXM-AX)-its skin tissue levels and clinical efficacy",
abstract = "The fundamental and clinical studies were performed on Cefuroxime axetil (CXM-AX, SN 407), a new oral cephalosporin, prodrug of Cefuroxime (CXM). The results are summarised below. 1. The mean serum levels of CXM at 120–150 minutes after oral administration of 250 mg and 500 mg of CXM-AX were 3. 25 μg/ml and 4. 30 μg/ml, and the corresponding mean skin tissue levels were 1.46 μg/g and 2.14 μg/g, respectively. The rates of transfer of CXM into skin tissues were 44.9{\%} and 59.5{\%}, respectively, showing dose response between 250 mg and 500 mg groups. 2. Out of 234 cases assessable for clinical efficacy, 122 cases were assessed as Cured, 58 Remarkably Improved, 28 Moderately Improved, 20 Slightly Improved, 5 Unchanged and 1 Aggravated, with the efficacy rate (“Moderately Improved” or better) being 88. 9{\%}. When the clinical efficacy was compared among groups of different diagnosis, the efficacy rates were 81.4{\%} (35/43) in the Group I, 92.5{\%} (37/40) in the Group II, 95.7{\%} (22/23) in the Group III, 90.9{\%} (40/44) in the Group IV, 94.6{\%} (53/56) in the Group V and 75. 0{\%} (21/28) in the Group VI. 3. Concerning the bacteriological response of the causative organisms, isolated from 169 patients, the bacterial elimination rate was 92. 3{\%} (132/143). The MIC peaks of CXM, against 96 strains of S. aureus and 39 strains of coagulase negative staphylococci (CNS), both of which were the major clinical isolates, were 1.56 μg/ml and 0. 78 μg/ml, respectively. The antibacterial activity of CXM was higher than that of Cephalexin (CEX) and comparable to that of Cefaclor (CCL). 4. Among 245 cases in which the safety of the drug was evaluated, adverse events were observed in 17 cases (6. 9{\%}), most of them being gastrointestinal tract symptoms, c. g. diarrhoea, loose stool and gastric pain. The abnormal laboratory findings were noted in a total of 11 cases, i. e. decrease in WBC counts in 2 cases (1.4{\%}), increase in eosinophil counts in 1 (0.7{\%}), elevation of hepatic transaminase levels in 7 (5. 0{\%}) and positive reaction in direct Coombs’ test in 1 (5. 6{\%}).",
author = "Atsushi Kukita and Hidemi Nakagawa and Shinichi Watanabe and Masataka Oji and Masutaka Furue and Michiro Shimozuma and Ryoji Watanabe and Takashi Eto and Ken Iozumi",
year = "1986",
month = "1",
day = "1",
doi = "10.11250/chemotherapy1953.34.Supplement5_967",
language = "English",
volume = "34",
pages = "967--1005",
journal = "CHEMOTHERAPY",
issn = "0009-3165",

}

TY - JOUR

T1 - Studies on cefuroxime axetil (CXM-AX)-its skin tissue levels and clinical efficacy

AU - Kukita, Atsushi

AU - Nakagawa, Hidemi

AU - Watanabe, Shinichi

AU - Oji, Masataka

AU - Furue, Masutaka

AU - Shimozuma, Michiro

AU - Watanabe, Ryoji

AU - Eto, Takashi

AU - Iozumi, Ken

PY - 1986/1/1

Y1 - 1986/1/1

N2 - The fundamental and clinical studies were performed on Cefuroxime axetil (CXM-AX, SN 407), a new oral cephalosporin, prodrug of Cefuroxime (CXM). The results are summarised below. 1. The mean serum levels of CXM at 120–150 minutes after oral administration of 250 mg and 500 mg of CXM-AX were 3. 25 μg/ml and 4. 30 μg/ml, and the corresponding mean skin tissue levels were 1.46 μg/g and 2.14 μg/g, respectively. The rates of transfer of CXM into skin tissues were 44.9% and 59.5%, respectively, showing dose response between 250 mg and 500 mg groups. 2. Out of 234 cases assessable for clinical efficacy, 122 cases were assessed as Cured, 58 Remarkably Improved, 28 Moderately Improved, 20 Slightly Improved, 5 Unchanged and 1 Aggravated, with the efficacy rate (“Moderately Improved” or better) being 88. 9%. When the clinical efficacy was compared among groups of different diagnosis, the efficacy rates were 81.4% (35/43) in the Group I, 92.5% (37/40) in the Group II, 95.7% (22/23) in the Group III, 90.9% (40/44) in the Group IV, 94.6% (53/56) in the Group V and 75. 0% (21/28) in the Group VI. 3. Concerning the bacteriological response of the causative organisms, isolated from 169 patients, the bacterial elimination rate was 92. 3% (132/143). The MIC peaks of CXM, against 96 strains of S. aureus and 39 strains of coagulase negative staphylococci (CNS), both of which were the major clinical isolates, were 1.56 μg/ml and 0. 78 μg/ml, respectively. The antibacterial activity of CXM was higher than that of Cephalexin (CEX) and comparable to that of Cefaclor (CCL). 4. Among 245 cases in which the safety of the drug was evaluated, adverse events were observed in 17 cases (6. 9%), most of them being gastrointestinal tract symptoms, c. g. diarrhoea, loose stool and gastric pain. The abnormal laboratory findings were noted in a total of 11 cases, i. e. decrease in WBC counts in 2 cases (1.4%), increase in eosinophil counts in 1 (0.7%), elevation of hepatic transaminase levels in 7 (5. 0%) and positive reaction in direct Coombs’ test in 1 (5. 6%).

AB - The fundamental and clinical studies were performed on Cefuroxime axetil (CXM-AX, SN 407), a new oral cephalosporin, prodrug of Cefuroxime (CXM). The results are summarised below. 1. The mean serum levels of CXM at 120–150 minutes after oral administration of 250 mg and 500 mg of CXM-AX were 3. 25 μg/ml and 4. 30 μg/ml, and the corresponding mean skin tissue levels were 1.46 μg/g and 2.14 μg/g, respectively. The rates of transfer of CXM into skin tissues were 44.9% and 59.5%, respectively, showing dose response between 250 mg and 500 mg groups. 2. Out of 234 cases assessable for clinical efficacy, 122 cases were assessed as Cured, 58 Remarkably Improved, 28 Moderately Improved, 20 Slightly Improved, 5 Unchanged and 1 Aggravated, with the efficacy rate (“Moderately Improved” or better) being 88. 9%. When the clinical efficacy was compared among groups of different diagnosis, the efficacy rates were 81.4% (35/43) in the Group I, 92.5% (37/40) in the Group II, 95.7% (22/23) in the Group III, 90.9% (40/44) in the Group IV, 94.6% (53/56) in the Group V and 75. 0% (21/28) in the Group VI. 3. Concerning the bacteriological response of the causative organisms, isolated from 169 patients, the bacterial elimination rate was 92. 3% (132/143). The MIC peaks of CXM, against 96 strains of S. aureus and 39 strains of coagulase negative staphylococci (CNS), both of which were the major clinical isolates, were 1.56 μg/ml and 0. 78 μg/ml, respectively. The antibacterial activity of CXM was higher than that of Cephalexin (CEX) and comparable to that of Cefaclor (CCL). 4. Among 245 cases in which the safety of the drug was evaluated, adverse events were observed in 17 cases (6. 9%), most of them being gastrointestinal tract symptoms, c. g. diarrhoea, loose stool and gastric pain. The abnormal laboratory findings were noted in a total of 11 cases, i. e. decrease in WBC counts in 2 cases (1.4%), increase in eosinophil counts in 1 (0.7%), elevation of hepatic transaminase levels in 7 (5. 0%) and positive reaction in direct Coombs’ test in 1 (5. 6%).

UR - http://www.scopus.com/inward/record.url?scp=0022969458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022969458&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.34.Supplement5_967

DO - 10.11250/chemotherapy1953.34.Supplement5_967

M3 - Article

VL - 34

SP - 967

EP - 1005

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

SN - 0009-3165

ER -